Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 637-641

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Avanzas, Pablo ^c   Gomez, Maria Angeles ^a   Kaski, Juan Carlos ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

C reactive protein; Cardiac syndrome X; Inflammation; Soluble CD40 ligand; White blood cells

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY RISK; EXERCISE; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MYOCARDIAL PERFUSION IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT DEPRESSION; SYNDROME X;

C-REACTIVE PROTEIN; CD40 LIGAND; EXERCISE TEST; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MICROVASCULAR ANGINA; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PROSPECTIVE STUDIES;

EID: 78649759351     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.031     Document Type: Article

References (36)

1. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003, 169:203-214.
2. Teragawa H., Fukuda Y., Matsuda K., et al. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart 2004, 90:750-754.
3. Arroyo-Espliguero R., Mollichelli N., Avanzas P., et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J 2003, 24:2006-2011.
4. Cosín-Sales J., Pizzi C., Brown S., et al. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003, 41:1468-1474.
5. Henn V., Slupsky J.R., Gräfe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
6. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
7. Schönbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
8. Graf D., Muller S., Korthauer U., et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995, 25:1749-1754.
9. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
10. Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P., et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis 2009, 206:523-527.
11. Garlichs C.D., Kozina S., Fateh-Moghadam S., et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
12. Harding S.A., Sommerfield A.J., Sarma J., et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004, 176:321-325.
13. Schönbeck U., Varo N., Libby P., et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-2268.
14. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., et al. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res 2007, 121:293-299.
15. Leslie W.D., Tully S.A., Yogendran M.S., et al. Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging. J Nucl Med 2005, 46:204-211.
16. Sharir T., Germano G., Kang X., et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. J Nucl Med 2001, 42:831-837.
17. Dominguez-Rodriguez A., Abreu-Gonzalez P., Kaski J.C. Inflammatory systemic biomarkers in setting acute coronary syndromes-effects of the diurnal variation. Curr Drug Targets 2009, 10:1001-1008.
18. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., et al. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res 2009, 123:617-621.
19. Antoniades C., Bakogiannis C., Tousoulis D., et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54:669-677.
20. Tousoulis D., Davies G.J., Asimakopoulos G., et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 2001, 24:301-304.
21. Metha J., Metha P. Comparison of platelet function during exercise in normal subjects and coronary artery disease patients: potential role of platelet activation in myocardial ischemia. Am Heart J 1982, 103:49-53.
22. Andreotti F., Lanza G.A., Sciahbasi A., et al. Low grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. Am J Cardiol 2001, 87:16-20.
23. Lanza G.A., Andreotti F., Sestito A., et al. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001, 65:1924-1930.
24. Lanza G.A., Aurigemma C., Fattorossi A., et al. Changes in platelet receptor expression and leukocyte-platelet agregate formation following exercise in cardiac syndrome X. J Thromb Haemost 2006, 4:1623-1625.
25. Andreotti F., Sciahbasi A., De Marco E., et al. Preinfarction angina and improved reperfusion of the infarct-related artery. Thromb Haemost 1999, 82(Suppl.):68-72.
26. Piret A., Niset G., Depiesse E., et al. Increased platelet aggregability and prostacyclin biosynthesis induced by intense physical exercise. Thromb Res 1990, 57:685-695.
27. Kaski J.C. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004, 109:568-572.
28. Diodati J.G., Dakak N., Gilligan D.M., et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998, 98:17-24.
29. Li J.J., Zhu C.G., Nan J.L., et al. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine 2007, 40:172-176.
30. Li J.J., Li Y.S., Zhang Y., et al. Inflammation: a possible pathogenic link to cardiac syndrome X. Med Hypotheses 2006, 66:527-530.
31. Fichtlscherer S., Rosenberger G., Walter D.H., et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
32. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
33. Arroyo-Espliguero R., Kaski J.C. Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ 2006, 174:1833.
34. Han S.H., Koh K.K., Quon M.J., et al. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007, 190:205-211.
35. Koh K.K., Quon M.J., Han S.H., et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 +2 in patients with type 2 diabetes. Atherosclerosis 2007, 194:230-237.
36. Tousoulis D., Antoniades C., Nikolopoulou A., et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007, 37:623-628.